The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ACCRU-GI-1810: Trifluridine/tipiracil (FTD-TPI) or paclitaxel (PAC) in combination with ramucirumab (RAM) for patients (pts) with previously treated advanced gastroesophageal adenocarcinoma (GEA)—An investigator-initiated, randomized non-inferiority phase 2 study.
 
Mohamad Sonbol
Honoraria - Novartis
Consulting or Advisory Role - Bayer (Inst); Boehringer Ingelheim (Inst)
Research Funding - Lilly (Inst); Taiho Oncology (Inst)
 
Angela Ulrich
No Relationships to Disclose
 
Fang-Shu Ou
No Relationships to Disclose
 
Anina Peersen
Employment - Mayo Clinic
 
Daniel Ahn
Stock and Other Ownership Interests - Lilly; Natera
Consulting or Advisory Role - Advanced Accelerator Applications; Daiichi Sankyo/Astra Zeneca; Eisai; Exelixis; Genentech/Roche; Incyte; Incyte; Novartis
Research Funding - AstraZeneca; Bayer
 
Jason Starr
Consulting or Advisory Role - Exelixis
Research Funding - Amgen (Inst); Aminex (Inst); Arcus Biosciences (Inst); Camurus (Inst); RayzeBio (Inst); Viewpoint Molecular Targeting (Inst)
 
Anthony Jaslowski
No Relationships to Disclose
 
Arun Nagarajan
No Relationships to Disclose
 
Syma Iqbal
Honoraria - Astellas Scientific and Medical Affairs Inc; AstraZeneca; BeiGene; Exelixis; Jazz Pharmaceuticals; Merck
Consulting or Advisory Role - AstraZeneca; BeiGene; Cardiff Oncology; Exelixis; Jazz Pharmaceuticals; Merck
Speakers' Bureau - Astellas Pharma
Travel, Accommodations, Expenses - Astellas Pharma; BeiGene; Exelixis
 
Michael Gibson
Stock and Other Ownership Interests - PapiVax Biotech, Inc.; PharmaJet
Honoraria - Astellas Pharma; Coherus Biosciences; Daiichi Sankyo/Lilly; Regeneron
Consulting or Advisory Role - Abbvie; regeneron; UpToDate
Research Funding - Daiichi Sankyo/Lilly (Inst); Juntendo University Medical Center (Inst); PapiVax Biotech, Inc. (Inst)
 
Tanios Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Caladrius Biosciences; Caladrius Biosciences; Celularity; Daiichi Sankyo/UCB Japan; Deciphera; Eisai; Eisai; Exact Sciences; Foundation Medicine; Foundation Medicine; Illumina; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Kanaph Therapeutics; Lilly (Inst); Natera; Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SOBI; Stemline Therapeutics; Treos Bio; Zai Lab
Patents, Royalties, Other Intellectual Property - Patent WO/2018/183488; Patent WO/2019/055687
Other Relationship - 1Globe Health Institute; AstraZeneca; Exelixis; FibroGen; Imugene; Lilly; Merck (Inst); Pancreatic Cancer Action Network; Replimune; Sun Biopharma; Suzhou Kintor Pharmaceuticals; UpToDate; Xilis